SCNX
New distribution deal, same very capitalist goal
Scienture is trying to push REZENOPY further into the real world, announcing an agreement with a distribution partner aimed at addiction treatment centers. In plain English: the company wants its product in more doors, on more formularies, and closer to patients who might actually use it.
Why this matters
For smaller drug companies, the jump from “approved or available” to “actually getting sold” is where the fun starts. Distribution deals can be boring on paper, but they’re often the plumbing that decides whether a product becomes a business or stays a science project.
What investors should watch
- Whether REZENOPY starts showing up in more treatment-center channels
- Any follow-up on sales momentum, inventory orders, or new commercial partnerships
- Whether Scienture can turn broader access into something that looks like repeatable revenue
Big picture: sometimes the most important part of a drug story isn’t the molecule — it’s the part where someone finally agrees to distribute it.